Janet Watts, PhD

Becton, Dickinson and Company (BD)

Disclosure(s): Becton, Dickinson and Company: Employee of Becton, Dickinson and Company, and the company received funding from GlaxoSmithKline plc. to conduct this study; GlaxoSmithKline plc.: GlaxoSmithKline plc.-sponsored study 212502

Poster(s):

• 426 - Trends in carbapenem non-susceptible (Carb-NS) Enterobacterales from hospitalized patients in the US from 2014-2020: A comparison between organisms with and without concerns for chromosomal ampC beta-lactamase hyperproduction
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 2225 - Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 2226 - Analysis of Co-Resistance Among Klebsiella pneumoniae Urine Isolates From Female Outpatients in the United States
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET